Guardant Health Inc., a precision oncology company, has announced the launch of the Guardant Hereditary Cancer test. This germline test is designed to identify genetic variants associated with cancer risk, aiding healthcare providers in delivering optimal patient care. The test can be ordered for patients with a personal or family history of hereditary cancer to guide treatment decisions, assess risk for secondary cancers, and potentially identify other at-risk family members. Requiring only a blood draw, the test results are available within two to three weeks. The Guardant Hereditary Cancer test analyzes 82 genes linked to increased risk for over 12 tumor types, including breast, colorectal, and prostate cancers.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。